DAEWOONG CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18,820 KRW | +0.64% |
|
+3.75% | -8.86% |
| Apr. 24 | Korean Sugar Imports Plunge 14% as Diabetes Cases Surge | MT |
| Mar. 08 | Daewoong Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
Strengths
- The company shows low valuation levels, with an enterprise value at 408.88 times its sales.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -8.86% | 556M | - | ||
| +19.27% | 43.75B | B- | ||
| +24.60% | 22.06B | B+ | ||
| +15.11% | 14.46B | - | ||
| +12.33% | 13.62B | B+ | ||
| +38.36% | 11.61B | B | ||
| -8.47% | 6.9B | B+ | ||
| -0.05% | 6.79B | - | - | |
| -8.87% | 5.73B | - | - | |
| +10.21% | 5.32B | B+ |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances
Valuation
P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
-
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- A003090 Stock
- Ratings Daewoong Co., Ltd.
